FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 4 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma MOST POPULAR Five Questions With…Desiree. April 21, 2022 Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 Hope and Challenge: The NCI Annual Plan and Budget Proposal for... September 24, 2018 Five Questions With…Sharon. May 12, 2022 Load more HOT NEWS Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ Should Surgery And Radiation Be The Standard Treatment For DCIS? The... Protecting Your Skin From the Sun All Year: Why It’s Important...
